WuXi Biologics, Bioasis in Supply Pact
By

WuXi Biologics, part of WuXi AppTec, a contract service provider, has partnered with Bioasis Technologies, a Richmond, British Columbia, Canada-based biopharmaceutical company focused on drug-delivery across the brain–blood barrier, to develop and manufacture xB3-001, Bioasis’ lead investigational biological candidate to treat brain cancer.

Bioasis is a biopharmaceutical company developing xB3, a proprietary platform technology for the delivery of therapeutics across the brain–blood barrier and treating central nervous system disorders, including brain cancers and neurodegenerative diseases.

Through this partnership, Bioasis will have access to WuXi Biologics’ technologies from cell-line construction and development, cell-culture process development, purification process development, and formulation development.

Source: Bioasis

Leave a Reply

Your email address will not be published. Required fields are marked *